Slide 1: Q4 2024 Earnings
Q4 2024 Earnings Chloe Podder since 2021 February 20, 2025 The Pod has an IP28 rating for up to 25 feet for 60 minutes. The PDM and Controller are not waterproof.
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements regarding, among other things, future operating and financial performance, product success and efficacy, the outcome of studies and trials, and the approval of products by regulatory bodies. These forward-looking statements
Slide 3: Non-GAAP Financial Measures
Non-GAAP Financial Measures The Company uses the following non-GAAP financial measures: • Constant currency revenue growth, which represents the change in revenue between current and prior-year periods using the exchange rate in effect during the applicable prior year period. Insulet presents consta
Slide 4: Q4 2024 Performance
Q4 2024 Performance1 Total Revenue Omnipod Revenue by Geography Other Financial Highlights U.S. Omnipod $443.7M GR OS S M AR GIN 12.4% 72.1% Total Company Total Omnipod $597.5M $585.7M up 120 bps 17.2%, 16.9%, 17.1% constant currency 16.8% constant currency O P ER AT IN G M A RG IN International Omn
Slide 5: FY 2024 Performance
FY 2024 Performance1 Total Revenue Omnipod Revenue by Geography Other Financial Highlights GR OS S M AR GIN U.S. Omnipod $1.5B 69.8% 20.6% up 210 bps Total Company Total Omnipod $2.1B $2.0B O P ER AT IN G M A RG IN 14.9% 22.1%, 22.4%, 21.9% constant currency 22.2% constant currency up 260 bps Intern
Slide 6: Progress Against Our Three Strategic Objectives
Progress Against Our Three Strategic Objectives Advance Lead Drive Omnipod 5 Platform with Innovation U.S. Growth in T1D & T2D Access Internationally • Announced Omnipod 5 integrated • #1 in new customer starts in 2024 • Launched Omnipod 5 with with Abbott’s FSL2+ CGM sensor in U.S.2 Abbott’s FSL2+
Slide 7: Q4 2024 Commercial Metrics
Q4 2024 Commercial Metrics Delivered NCS Growth: • YoY & QoQ • in U.S. & International • in T1D & T2D O VE R O VE R O VE R O VE R 85% 30% 90% 30% of U.S. NCS of U.S. NCS of U.S. Customer of International were MDI were T2D Base with Omnipod Customer Base with 5 Omnipod 5 7 Note: Some commercial metri
Slide 8: FY 2025 Guidance
FY 2025 Guidance1 Revenue Guidance2 Margin Guidance Assumptions & Drivers Q1 2025 FY 2025 FY 2025 FY 2025 Continued strong Omnipod 5 Revenue Gross Margin Operating Margin adoption globally Revenue U.S. & International annual NCS growth 22% - 25% 16% - 20% ~70.5% ~16.5% YoY fueled by cascade of innov
Slide 9: Appendix
Appendix Insulet
Slide 10: Insulet Common Abbreviations and Acronyms
Insulet Common Abbreviations and Acronyms AID Automated Insulin Delivery MDI Multiple Daily Injections bps Basis Points NCS New Customer Starts CGM Continuous Glucose Monitoring PDM Personal Device Manager FSL2+ Abbott FreeStyle Libre 2 Plus Sensor QoQ Quarter-over-Quarter G6 Dexcom G6 Sensor T1D Ty
Slide 11: Q4 2024 Financial Performance
Q4 2024 Financial Performance1 $s in Millions Total Revenue Total Omnipod Gross Profit & Margin U.S. Omnipod International Omnipod Operating Income & Margin 1. Revenue growth is on a YoY basis and is in constant currency. Gross margin and operating margin YoY comparisons are to prior year adjusted g
Slide 12: FY 2024 Financial Performance
FY 2024 Financial Performance1 $s in Millions Total Revenue Total Omnipod Gross Profit & Margin 1 1 U.S. Omnipod International Omnipod Operating Income & Margin 1 1 1. Revenue growth is on a YoY basis. Constant currency is a non-GAAP measure. For the periods indicated, gross margin and operating mar
Slide 13: Non-GAAP Reconciliation — Revenue Guidance
Non-GAAP Reconciliation — Revenue Guidance Year Ending December 31, 2025 Revenue Growth GAAP Currency Impact Constant Currency U.S. Omnipod 16% to 20% —% 16% to 20% International Omnipod 19% to 23% (3)% 22% to 26% Total Omnipod 16% to 20% (1)% 17% to 21% Drug Delivery (55)% to (45)% —% (55)% to (45)
Slide 14: Reconciliation of Historical Non-GAAP Measures
Reconciliation of Historical Non-GAAP Measures % of % of % of % of % of % of FY2024 FY2023 FY2022 FY2021 Q4 2024 Q4 2023 Revenue Revenue Revenue Revenue Revenue Revenue Total Revenue GAAP Growth Rate 22.1% 30.0% 18.8% 21.5% 17.2% 37.9% Less: Currency Impact 0.2% 0.4% (3.7)% 1.8% 0.1% 1.3% Constant C